PDPN and neoplasm: For example, loading a CAR-T cell with tumour-specific mAbs can help overcome the on-target/off-tumour cross-reactivity of some CAR-T cells with both glioma and normal cells, such as in Lp2 CAR-T cells loaded with LpMab-2 to target podoplanin (PDPN)-expressing glioma cells whilst sparing PDPN-expressing normal cells, when used with G47Δ [90].